Abstract:Background: Mitochondrial dysfunction and metabolic reprogramming can lead to the development and progression of hepatocellular carcinoma (HCC). Ferredoxin 1 (FDX1) is a small mitochondrial protein and recent studies have shown that FDX1 plays an important role in tumor cuproptosis, but its role in HCC is still elusive. In this study, we aim to investigate the expression and novel functions of FDX1 in HCC. Methods: FDX1 expression was first analyzed in publicly available datasets and verified by immunohistochemistry, qRT-PCR and Western blot. In vitro and in vivo experiments were applied to explore the functions of FDX1. Non-targeted metabolomics and RNA-sequencing were used to determine molecular mechanism. mRFP-GFP-LC3 lentivirus transfection, Mito-Tracker Red and Lyso-Tracker Green staining, transmission electron microscopy, flow cytometry, JC-1 staining, etc. were used to analyze mitophagy or ROS levels. Hydrodynamic tail vein injection (HTVi) and patient-derived organoid (PDO) models were used to analyze effect of FDX1 overexpression. Results: FDX1 expression is significantly downregulated in HCC tissues. FDX1 downregulation promotes HCC cell proliferation, invasion in vitro and growth, metastasis in vivo. In addition, FDX1 affects metabolism of HCC cells and is associated with autophagy. We then confirmed that FDX1 deficiency increases ROS levels, activates mitophagy and the PI3K/AKT signaling pathway in HCC cells. Interestingly, scavenging ROS attenuates the tumor-promoting role and mitophagy of FDX1 downregulation. The results of HTVi and PDO models both find that FDX1 elevation significantly inhibits HCC progression. Moreover, low FDX1 expression is associated with shorter survival and is an independent risk factor for prognosis in HCC patients. Conclusions: Our research had investigated novel functions of FDX1 in HCC. Downregulation of FDX1 contributes to metabolic reprogramming and leads to ROS-mediated activation of mitophagy and the PI3K/AKT signaling pathway. FDX1 is a potential prognostic biomarker and increasing FDX1 expression may be a potential therapeutic approach to inhibit HCC progression.

Repressing of NHERF1 Inhibits Liver Cancer Progression by Promoting the Production of ROS.

Loss of Neuropilin1 Inhibits Liver Cancer Stem Cells Population and Blocks Metastasis in Hepatocellular Carcinoma Via Epithelial-Mesenchymal Transition

NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF‐1α signaling in hepatocellular carcinoma

NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF-1 signaling in hepatocellular carcinoma

Hnf6 Promotes Tumor Growth In Colorectal Cancer And Enhances Liver Metastasis In Mouse Model

Hepatocellular carcinoma cells downregulate NADH:Ubiquinone Oxidoreductase Subunit B3 to maintain reactive oxygen species homeostasis

Hypoxia-inducible Long Noncoding RNA NPSR1-AS1 Promotes the Proliferation and Glycolysis of Hepatocellular Carcinoma Cells by Regulating the MAPK/ERK Pathway

Loss of neuropilin 1 inhibits liver cancer stem cells population and blocks metastasis in 6 hepatocellular carcinoma via epithelial-mesenchymal transition 7 8

Nuclear Respiratory Factor 1 Drives Hepatocellular Carcinoma Progression by Forming a Positive Feedback Loop with LPCAT1-ERK1/2-CREB Axis

Nrf1 is Endowed with a Dominant Tumor-Repressing Effect Onto the Wnt/β-Catenin-Dependent and Wnt/β-Catenin-Independent Signaling Networks in the Human Liver Cancer

STAT3 and AKT Signaling Pathways Mediate Oncogenic Role of NRSF in Hepatocellular Carcinoma

Nuclear Respiratory Factor 1 Drives Hepatocellular Carcinoma Progression by Activating LPCAT1-ERK1/2-CREB Axis

Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway

Sel1L-Hrd1 ER-Associated Degradation Suppresses Hepatocyte Hyperproliferation and Liver Cancer

TALENs-directed Knockout of the Full-Length Transcription Factor Nrf1α That Represses Malignant Behaviour of Human Hepatocellular Carcinoma (hepg2) Cells.

NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma

NRP-1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo.

FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production

Downregulation of Low-density Lipoprotein Receptor-Related Protein 1B (LRP1B) Inhibits the Progression of Hepatocellular Carcinoma Cells by Activating the Endoplasmic Reticulum Stress Signaling Pathway.

PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway

Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma